Sugi Predict

Sugi Predict / Compounds / SCHEMBL1095307

SCHEMBL1095307

SCHEMBL1095307

C[C@@H]1CNCCc2cc(Cl)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 20/20 1.00
▸ HTR2A P28223 17/20 1.00
▸ HTR2B P41595 16/20 1.00
▸ ADRB1 P08588 1/20 0.79
▸ HTR1A P08908 1/20 0.79
▸ ADRA2A P08913 1/20 0.79
▸ ADRA2B P18089 1/20 0.79
▸ ADRA2C P18825 1/20 0.79
▸ CNR1 P21554 1/20 0.79
▸ SLC6A2 P23975 1/20 0.79
▸ SLC6A4 P31645 1/20 0.79
▸ HRH1 P35367 1/20 0.79
▸ KCNH2 Q12809 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1095306 1.00 HTR2C (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
SCHEMBL1105044 1.00 HTR2C (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL169382 0.88 HTR2A (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL29349440 0.88 HTR2A (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL5946555 0.88 HTR2A (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL1094953 0.88 HTR2A (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL170848 0.88 HTR2A (1.00) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL16672993 0.87 HTR2A (0.97) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL1954700 0.87 HTR2A (0.97) HTR2CHTR2AHTR2BADRB1HTR1A
Lorcaserin SCHEMBL174044 0.87 HTR2A (0.97) HTR2CHTR2AHTR2BADRB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374796-B1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes ARENA PHARM INC (US) 2018-02-28 — — EP disclosed
US-20160250223-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2016-09-01 — — US disclosed
US-20160024014-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2016-01-28 — — US disclosed
US-8993750-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2015-03-31 — — US disclosed
US-20150087634-A1 5HT2C RECEPTOR MODULATOR COMPOSITIONS ARENA PHARMACEUTICALS, INC. 2015-03-26 — — US disclosed
US-20150045552-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2015-02-12 — — US disclosed
US-8846906-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-8575149-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2013-11-05 — — US disclosed
US-8546378-B2 5HT2C receptor modulator compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2013-10-01 — — US disclosed
US-8546379-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2013-10-01 — — US disclosed
EP-1833473-B1 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE ARENA PHARM INC (US) 2009-09-09 — — EP disclosed
US-20090197868-A1 5ht2c receptor modulator compositions and methods of use ARENA PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed
US-7514422-B2 5HT2c receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2009-04-07 — — US disclosed
US-20070060568-A1 Obesity therapy; using 3-benzoazepine compound ARENA PHARMACEUTICALS, A DELAWARE CORPORATION 2007-03-15 — — US disclosed
EP-1411881-B9 5HT2C RECEPTOR MODULATORS ARENA PHARM INC (US) 2006-11-15 — — EP disclosed
US-6953787-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2005-10-11 — — US disclosed
EP-1557409-A1 5HT2C receptor modulators Arena Pharmaceuticals, Inc. (US) 2005-07-27 — — EP disclosed
EP-1411881-B1 5HT2C RECEPTOR MODULATORS ARENA PHARM INC (US) 2005-05-04 — — EP disclosed
US-20050020573-A1 Obesity; using 3-benoazepine compound ARENA PHARMACEUTICALS, INC. (US) 2005-01-27 — — US disclosed
US-20030225057-A1 3-Benzoazepine derivatives ARENA PHARMACEUTICALS, INC. (US) 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225057-A1 3-Benzoazepine derivatives HTR2C, HTR1A, HTR3A HTR2C 1/4885HTR2A 13/4885HTR2B 10/4885
US-20050020573-A1 Obesity; using 3-benoazepine compound HTR2C, HTR3C, HTR3B HTR2C 1/4885HTR2A 7/4885HTR2B 14/4885
US-20070060568-A1 Obesity therapy; using 3-benzoazepine compound HTR2C, HTR3B, HTR3C HTR2C 1/4885HTR2A 8/4885HTR2B 6/4885
US-20150087634-A1 5HT2C RECEPTOR MODULATOR COMPOSITIONS HTR2C, HTR2A, HTR5A HTR2C 1/4885HTR2A 2/4885HTR2B 10/4885
US-20160024014-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885
US-20090197868-A1 5ht2c receptor modulator compositions and methods of use HTR2C, HTR5A, HTR2A HTR2C 1/4885HTR2A 3/4885HTR2B 11/4885
US-20150045552-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885
US-20160250223-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.